C4 Therapeutics (CCCC) Non-Current Assets (2019 - 2025)
Historic Non-Current Assets for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $58.6 million.
- C4 Therapeutics' Non-Current Assets fell 4299.05% to $58.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $309.2 million, marking a year-over-year decrease of 2840.24%. This contributed to the annual value of $91.8 million for FY2024, which is 1275.58% down from last year.
- Per C4 Therapeutics' latest filing, its Non-Current Assets stood at $58.6 million for Q3 2025, which was down 4299.05% from $71.8 million recorded in Q2 2025.
- In the past 5 years, C4 Therapeutics' Non-Current Assets ranged from a high of $212.5 million in Q1 2022 and a low of $50.9 million during Q2 2021
- Over the past 5 years, C4 Therapeutics' median Non-Current Assets value was $105.0 million (recorded in 2024), while the average stood at $111.3 million.
- In the last 5 years, C4 Therapeutics' Non-Current Assets skyrocketed by 84660.46% in 2021 and then plummeted by 4467.65% in 2023.
- Over the past 5 years, C4 Therapeutics' Non-Current Assets (Quarter) stood at $181.1 million in 2021, then decreased by 20.87% to $143.3 million in 2022, then fell by 26.54% to $105.3 million in 2023, then fell by 12.76% to $91.8 million in 2024, then crashed by 36.16% to $58.6 million in 2025.
- Its Non-Current Assets stands at $58.6 million for Q3 2025, versus $71.8 million for Q2 2025 and $87.0 million for Q1 2025.